Page 9 Medical & Healthcare Expert Guide 2019
P. 9
9
Cenna Biosciences Inc. is dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer’s
disease (AD). Cenna was founded in 2006 as a California C-corporation, to translate over a decade’s academic research
at the University of California at San Diego (UCSD) by the inventors of its technology. The proprietary technology
addresses the underlying cause of the disease, the inappropriate deposition of the toxic species, ß-amyloid (Aß), in
the brains of patients with AD. The Company has developed a novel target and is developing several lead peptide
compounds as disease-modifying drug candidates for the treatment of AD. Cenna’s novel technology does not
target ß- or γ-secretase, thus avoiding the inhibition or modulation of their other numerous substrates besides APP,
including Notch, that have confounded previous therapeutic efforts in the reduction of Aß. Cenna’s technology is also
the earliest in terms of intervention, as it stops the Aß from being produced, as opposed to dealing with the effects of
Aß once it has accumulated. It is anticipated that these therapeutics will have a significant impact in both treatment
and prevention modes and be useful throughout the course of disease. The work is at Pre-clinical stage and has so
far has been funded by non-diluting NIH and other grants. The Intellectual Property that forms the basis of Cenna’s
approach is covered by U.S. and foreign Patents, filed by UCSD and exclusively licensed to Cenna by UCSD.
Cenna Biosciences Inc. is dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer’s
disease (AD). Cenna was founded in 2006 as a California C-corporation, to translate over a decade’s academic research
at the University of California at San Diego (UCSD) by the inventors of its technology. The proprietary technology
addresses the underlying cause of the disease, the inappropriate deposition of the toxic species, ß-amyloid (Aß), in
the brains of patients with AD. The Company has developed a novel target and is developing several lead peptide
compounds as disease-modifying drug candidates for the treatment of AD. Cenna’s novel technology does not
target ß- or γ-secretase, thus avoiding the inhibition or modulation of their other numerous substrates besides APP,
including Notch, that have confounded previous therapeutic efforts in the reduction of Aß. Cenna’s technology is also
the earliest in terms of intervention, as it stops the Aß from being produced, as opposed to dealing with the effects of
Aß once it has accumulated. It is anticipated that these therapeutics will have a significant impact in both treatment
and prevention modes and be useful throughout the course of disease. The work is at Pre-clinical stage and has so
far has been funded by non-diluting NIH and other grants. The Intellectual Property that forms the basis of Cenna’s
approach is covered by U.S. and foreign Patents, filed by UCSD and exclusively licensed to Cenna by UCSD.
